<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040698</url>
  </required_header>
  <id_info>
    <org_study_id>JFR-001</org_study_id>
    <nct_id>NCT05040698</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa</brief_title>
  <official_title>An Exploratory, Proof-of-Concept Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Holdsworth House Medical Practice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Holdsworth House Medical Practice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 16 week exploratory, Proof of Concept study to evaluate the effect of Fostamatinib (12&#xD;
      weeks of treatment) upon cutaneous inflammation in Hidradenitis Suppurativa.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sample size: 20 patients Study duration: 16 weeks&#xD;
&#xD;
      Primary Endpoints:&#xD;
&#xD;
      Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+,&#xD;
      CD20+, CD138+) at Week 4 compared to Baseline.&#xD;
&#xD;
      Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+,&#xD;
      CD20+, CD138+) at Week 12 compared to Baseline.&#xD;
&#xD;
      Secondary Endpoints:&#xD;
&#xD;
      Safety and Tolerability (Grade 2/3 Adverse Effects); Changes in Disease Activity (Measures by&#xD;
      AN count and IHS4 scoring).&#xD;
&#xD;
      Study procedures Clinical Examination, Patient Questionnaires, Skin Biopsy, Blood Draw,&#xD;
      medical photography&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Week 4 evaluation</measure>
    <time_frame>4 weeks</time_frame>
    <description>Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 4 compared to</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Week 12 evaluation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Alterations in Gene Expression Profiling, cell counts (CD3+, CD11c+, Neutrophil Elastase+, CD20+, CD138+) at Week 12 compared to Baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade 2/3 Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of Grade 2/3 Adverse Effects of Fostamatinib over the 12 Week course of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscess and Nodule Count Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in Abscess and Nodule count at Week 4 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Hidradenitis Suppurativa Severity Score (IHS4) Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Changes in IHS4 score at Week 4 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abscess and Nodule count week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in Abscess and Nodule count at Week 12 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Hidradenitis Suppurativa Severity Score (IHS4) Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in IHS4 score at Week 12 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Rated Overall Disease Severity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in physician rated overall disease severity by visual analogue scale (0-10) at week 12 compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Changes in the DLQI (0-30) at week 12 compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hidradenitis Suppurativa</condition>
  <arm_group>
    <arm_group_label>Open Label Fostamatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label Fostamatinib 100mg dose adjusted by the Principal Investigator after week 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib</intervention_name>
    <description>Open label Fostamatinib</description>
    <arm_group_label>Open Label Fostamatinib</arm_group_label>
    <other_name>Tavalisse</other_name>
    <other_name>R935788</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Moderate to Severe (Hurley Stage 2 or 3) Hidradenitis Suppurativa as determined by the&#xD;
             PI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure [BP] ≥135 mmHg and/or diastolic BP&#xD;
             ≥85 mmHg), unstable angina, congestive heart failure of New York Heart Association&#xD;
             classification III or IV, serious cardiac arrhythmia requiring treatment (exceptions:&#xD;
             atrial fibrillation, paroxysmal supraventricular tachycardia) at screening.&#xD;
&#xD;
          -  History of myocardial infarction within 3 months prior to screening.&#xD;
&#xD;
          -  Shock or hypotension requiring vasoactive peptides, such as dopamine, norepinephrine,&#xD;
             epinephrine, or dobutamine at screening or at randomization.&#xD;
&#xD;
          -  Renal function impairment with creatinine clearance &lt;30 mL/min at screening (estimated&#xD;
             glomerular filtration rate will be calculated using the modification of diet in renal&#xD;
             disease equation).&#xD;
&#xD;
          -  Liver function impairment with aspartate aminotransferase/alanine aminotransferase&#xD;
             &gt;=3x the upper limit of normal or bilirubin &gt;2X the upper limit of normal at&#xD;
             screening.&#xD;
&#xD;
          -  Neutrophil count &lt;1000/µL at screening.&#xD;
&#xD;
          -  History of an allergic reaction or hypersensitivity to the study treatment or any&#xD;
             component of the study treatment formulation.&#xD;
&#xD;
          -  Has documented HIV infection or documented, active hepatitis B or hepatitis C&#xD;
             infection.&#xD;
&#xD;
          -  Women lactating, pregnant or of childbearing potential who are not willing to avoid&#xD;
             becoming pregnant during the study.&#xD;
&#xD;
          -  Individuals with concurrent use of systemic antibiotics/ oral retinoids/ systemic&#xD;
             immunosuppressants (those with prior use of these medications must have conducted a&#xD;
             washout period of 4 weeks or 5 half-lives of the drug, whichever is longer).&#xD;
&#xD;
          -  Any medical, psychological or social condition that, in the opinion of the&#xD;
             Investigator, would jeopardize the health or well-being of the participant during any&#xD;
             study procedures or the integrity of the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Frew, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Holdsworth House Medical Practice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trina Vincent, R.N.</last_name>
    <phone>+61280381044</phone>
    <email>trina.vincent@holdsworthhouse.com.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>John Frew, MBBS</last_name>
    <phone>02 93317228</phone>
    <email>john.frew@holdsworthhouse.com.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Trina Vincent, R.N.</last_name>
      <phone>0280381044</phone>
      <email>trina.vincent@holdsworthhouse.com.au</email>
    </contact>
    <contact_backup>
      <last_name>Georgia Rudevics</last_name>
      <phone>02 80381044</phone>
      <email>georgia.rudevics@holdsworthhouse.com.au</email>
    </contact_backup>
    <investigator>
      <last_name>John Frew, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 30, 2021</study_first_submitted>
  <study_first_submitted_qc>September 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Holdsworth House Medical Practice</investigator_affiliation>
    <investigator_full_name>John Frew</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>fostamatinib</keyword>
  <keyword>HS</keyword>
  <keyword>Tavalisse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

